Moreover, as already depicted in the CHK1 inhibitors section, synthetic lethality and therapeutic synergy, combining adavosertib with CHK1 inhibitors and with other DDR inhibitors, has been further successfully demonstrated in many tumor types, including melanoma [69,78,109,132]. This evidence concerns the gene CHEK1 and melanoma.